Recurrent mutations in tumor suppressor <i>FBXW7</i> bypass Wnt/β-catenin addiction in cancer.
Ontology highlight
ABSTRACT: Pathologic Wnt/β-catenin signaling drives various cancers, leading to multiple approaches to drug this pathway. Appropriate patient selection can maximize success of these interventions. Wnt ligand addiction is a druggable vulnerability in RNF43-mutant/RSPO-fusion cancers. However, pharmacologically targeting the biogenesis of Wnt ligands, e.g., with PORCN inhibitors, has shown mixed therapeutic responses, possibly due to tumor heterogeneity. Here, we show that the tumor suppressor FBXW7 is frequently mutated in RNF43-mutant/RSPO-fusion tumors, and FBXW7 mutations cause intrinsic resistance to anti-Wnt therapies. Mechanistically, FBXW7 inactivation stabilizes multiple oncoproteins including Cyclin E and MYC and antagonizes the cytostatic effect of
SUBMITTER: Zhong Z
PROVIDER: S-EPMC10990278 | biostudies-literature | 2024 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA